MwanzoPRENW • NASDAQ
Prenetics
$ 0.010
30 Sep, 14:20:26 GMT -4 · USD · NASDAQ · Kanusho
Hisa zinazouzwa Marekani
Bei iliyotangulia
$ 0.012
Bei za siku
$ 0.010 - $ 0.012
Bei za mwaka
$ 0.0042 - $ 0.060
Thamani ya kampuni katika soko
53.64M USD
Wastani wa hisa zilizouzwa
elfu 143.08
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD)Mac 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
6.41M-63.77%
Matumizi ya uendeshaji wa biashara
12.94M-35.05%
Mapato halisi
-8.57M21.92%
Kiwango cha faida halisi
-133.60-115.48%
Mapato kwa kila hisa
EBITDA
-8.06M25.95%
Asilimia ya kodi ya mapato
3.07%
Jumla ya mali
Jumla ya dhima
(USD)Mac 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
71.26M-62.57%
Jumla ya mali
243.59M-16.31%
Jumla ya dhima
40.82M-29.02%
Jumla ya hisa
202.76M
hisa zilizosalia
12.22M
Uwiano wa bei na thamani
0.00
Faida inayotokana na mali
-9.20%
Faida inayotokana mtaji
-10.98%
Mabadiliko halisi ya pesa taslimu
(USD)Mac 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
-8.57M21.92%
Pesa kutokana na shughuli
Pesa kutokana na uwekezaji
Pesa kutokana na ufadhili
Mabadiliko halisi ya pesa taslimu
Mtiririko huru wa pesa
Kuhusu
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer. Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions. The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Ilianzishwa
2014
Wafanyakazi
322
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu